Mereo BioPharma Group

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MREO and other ETFs, options, and stocks.

About MREO

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649).

CEO

Denise Vera Scots-Knight

CEODenise Vera Scots-Knight

Employees

Employees36

Headquarters

London, Greater London

HeadquartersLondon, Greater London

Founded

2015

Founded2015

Employees

Employees36

MREO Key Statistics

Market cap

45.69M

Market cap45.69M

Price-Earnings ratio

-1.08

Price-Earnings ratio-1.08

Dividend yield

—

Dividend yield—

Average volume

26.13M

Average volume26.13M

High today

$2.34

High today$2.34

Low today

$0.1948

Low today$0.1948

Open price

$0.2503

Open price$0.2503

Volume

241.45M

Volume241.45M

52 Week high

$3.84

52 Week high$3.84

52 Week low

$0.1948

52 Week low$0.1948

MREO News

TipRanks 12h

Mereo Biopharma Updates Setrusumab Trials and Cost Controls

Claim 70% Off TipRanks This Holiday Season Mereo Biopharma Group Plc ( (MREO) ) has shared an announcement. On December 29, 2025, Mereo BioPharma reported tha...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell